Inhibikase Therapeutics (IKT) Enterprise Value Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Enterprise Value Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.84% |
| Dec 31, 2025 | -83.27% |
| Sep 30, 2025 | -2,283.81% |
| Jun 30, 2025 | -1,004.10% |
| Mar 31, 2025 | -855.76% |
| Dec 31, 2024 | -636.06% |
| Sep 30, 2024 | 80.73% |
| Jun 30, 2024 | 62.07% |
| Mar 31, 2024 | 62.09% |
| Dec 31, 2023 | 42.51% |
| Sep 30, 2023 | 36.57% |
| Jun 30, 2023 | 35.01% |
| Mar 31, 2023 | 29.75% |
| Dec 31, 2022 | 43.44% |
| Sep 30, 2022 | 40.83% |
| Jun 30, 2022 | 31.22% |
| Mar 31, 2022 | -280.98% |
| Dec 31, 2021 | -192.04% |
| Sep 30, 2021 | -277,274.75% |
| Jun 30, 2021 | -601,525.64% |